Latest Commercial Partnerships News

Urbanise.com Limited reported a 4.2% revenue increase for FY2025, driven by a landmark partnership and equity investment from National Australia Bank. The company achieved positive operating cash flow for the fourth consecutive quarter, setting the stage for its next growth phase.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

Proteomics International Laboratories has secured $12 million to fast-track its precision diagnostic tests, including the US launch of PromarkerD for diabetic kidney disease, backed by a new AMA billing code. The company also advances its pipeline with new patents and commercial partnerships.

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

Novonix Limited reports significant progress in its synthetic graphite anode materials production, benefiting from new US tariffs on Chinese imports and strategic leadership appointments. The company also secures up to US$100 million in convertible debenture funding to support expansion plans.

Firebird Metals has secured two key patents for its proprietary Lithium Manganese Iron Phosphate (LMFP) battery materials, reinforcing its position in the emerging $20 billion LMFP market. The company’s integrated production approach and expanding IP portfolio set the stage for global growth amid shifting technology controls.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

Unith Ltd has raised $1.85 million through a strategic share placement to accelerate the growth of its AI-driven Digital Human platform and expand its global footprint. The capital injection aims to boost platform development, marketing, and partnerships across key regions including Europe, LATAM, MENA, and Australia.

Provaris Energy has raised $1.08 million through a share placement to accelerate its hydrogen and carbon dioxide storage and transport infrastructure development in Europe, including a prototype hydrogen tank program in Norway.

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

Horseshoe Metals has secured crucial Direct Shipping Ore mining approval for its Horseshoe Lights Copper-Gold Project, setting the stage for imminent production and early revenue generation from high-grade copper stockpiles.

Paradigm Biopharmaceuticals has locked in a $27 million USD convertible note facility to fully fund its pivotal Phase 3 trial for knee osteoarthritis, ensuring operational momentum through key clinical milestones.